August 24, 2021Fort Worth, Texas – Nacuity Pharmaceuticals, a clinical stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts, and other ocular diseases caused by oxidative stress, today announced the appointment of Robert R. Ruffolo, Ph.D., to its Board of Directors. A seasoned pharmaceutical executive, Dr. Ruffolo brings a wealth of experience in leading the […]

New York, NY (February 2nd, 2021) – LB Pharmaceuticals Inc, (“LB”) a biotechnology company focused on developing and commercializing novel and improved versions of successful CNS treatments, announced today the administration of the first dose of LB-102 in a Phase 1b clinical trial (Clinical Trials Identifier NCT04588129).This clinical study is designed to evaluate thedopamine receptor

MONTREAL (CANADA) – January 07, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced the U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease (RPD) designation to the Company’s lead compound, INV-101, for the treatment of Prader-Willi syndrome (PWS). A Phase I study with INV-101 is

Publication links maternal carriage of Prevotella during pregnancy with protection against infant food allergy March 25, 2020 Geelong, Australia March 25, 2020 – Prevatex Pty Ltd an emerging life sciences company focussed on developing and bringing to market next generation probiotics to restore and maintain healthy maternal and infant microbiomes, is pleased to report the

MONTREAL (CANADA) – September 29, 2020 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH). The trial will evaluate